{
    "2021-11-10": [
        [
            {
                "time": "2021-11-01",
                "original_text": "【兴证医药】辉瑞口服新冠药物进展及医药行业后续展望 -  医药行业周报(2021.11.01-2021.11.05)",
                "features": {
                    "keywords": [
                        "辉瑞",
                        "新冠药物",
                        "医药行业",
                        "进展",
                        "展望"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-11-01",
                "original_text": "高瓴易方达蓝筹后撤！营收利润双降，爱尔眼科持续收购是良药？ 盈利能力下降",
                "features": {
                    "keywords": [
                        "高瓴",
                        "易方达",
                        "蓝筹",
                        "爱尔眼科",
                        "收购",
                        "盈利能力",
                        "下降"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}